Funding for this research was provided by:
Breast Cancer Research Foundation (N/A)
Chan Soon Shiong Institute of Advanced Health (AUP-1010-0025)
Symphogen A/S (NA)
Received: 26 March 2019
Accepted: 15 April 2020
First Online: 15 May 2020
Ethics approval and consent to participate
: Tissues used to generate the patient-derived xenografts were collected from consenting patients following institutional review board-approved protocols at clinics in the Baylor College of Medicine and Ben Taub General Hospital (Houston, TX, USA), as previously reported [CitationRef removed], and at Houston Methodist Hospital Cancer Center (protocol Pro00005346).
: Not applicable, because the present article does not contain any individual person’s data in any form.
: Johan Lantto, Ivan D. Horak, and Michael Kragh are co-inventors on a patent owned by Symphogen A/S that describes the Pan-HER composition. The other authors declare that they have no competing interests.